Presented by the AHNS Population Health & Clinical Research Service

Join the AHNS and Dr. David Forner for a discussion with Dr. John de Almeida, surgeon investigator, and clinical trialist at the Princess Margaret Hospital in Toronto. In this interview, Dr. de Almeida gives an update on his oropharyngeal cancer trial, HN11 / SELECT, and provides advice and guidance for early clinician investigators.

Moderator:

Ameya Asarkar, MD – Ochsner-LSU Health

Panelists:

From the American Head & Neck Society:

Mirabelle Sajisevi, MD – University of Vermont Health Network

Ian Ganly, MD PhD – Memorial Sloan Kettering Cancer Center

From the Multidisciplinary Salivary Gland Society:

Boyd Gillespie, MD – University of Tennessee Health Science Center

Dott. Davide Lombardi – Azienda Spedali Civili, Brescia, Italy

Objectives

• Articulate the treatment extent standards for low grade salivary malignancies
• Appraise the current literature evidence for treatment standards, risk and recurrence rates for the malignancies
• Develop an evidence-based algorithm for management of patients with low grade salivary malignancies

REGISTER NOW

The American Head and Neck Society (AHNS) strongly supports the continued and widespread use of the human papillomavirus (HPV) vaccine as a vital public health measure to prevent HPV-associated cancers, including oropharyngeal cancers—the most rapidly rising HPV-related malignancy in the United States.

Scientific evidence has consistently demonstrated that HPV vaccination is safe, effective, and significantly reduces the incidence of infections that lead to HPV-related cancers and papillomas. As experts in the care and treatment of head and neck cancers, the AHNS recognizes the critical role that vaccination plays in reducing the burden of HPV-related diseases and ultimately saving lives.

We advocate for HPV vaccination for all eligible individuals, as recommended by the Centers for Disease Control and Prevention (CDC). Vaccination is most effective when administered before exposure to the virus, typically in adolescence, but catch-up vaccination remains safe and potentially beneficial for many adults up to the age of 45.

The AHNS urges healthcare providers, policymakers, educators, and community leaders to support public health initiatives that expand access to and education about the HPV vaccine. Together, we can take meaningful steps toward the prevention of HPV-related cancers and the advancement of long-term public health.

Sincerely,

The American Head and Neck Society